{
    "2019-06-28": [
        [
            {
                "time": "2019-06-28",
                "original_text": "海外医药新闻发布20190628【西南医药朱国广陈铁林团队】",
                "features": {
                    "keywords": [
                        "海外医药",
                        "新闻发布",
                        "西南医药",
                        "朱国广",
                        "陈铁林"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "复宏汉霖-B（2696.HK）：可负担的创新，值得期待的IPO？",
                "features": {
                    "keywords": [
                        "复宏汉霖",
                        "创新",
                        "IPO"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "豪掷7亿“收编”注射剂1类新药，这家药企或迎来第30个过亿单品",
                "features": {
                    "keywords": [
                        "7亿",
                        "注射剂",
                        "1类新药",
                        "药企",
                        "过亿单品"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医疗器械行业薪酬发布 年薪中位数——82万",
                "features": {
                    "keywords": [
                        "医疗器械",
                        "薪酬",
                        "年薪中位数"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗器械"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "投资地产医药主题基金时，了解这点赚更多！",
                "features": {
                    "keywords": [
                        "投资",
                        "地产医药",
                        "主题基金"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "房地产",
                        "基金"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "康哲药业逆势急升近6% 附属获干眼症药大中华商业权",
                "features": {
                    "keywords": [
                        "康哲药业",
                        "逆势急升",
                        "干眼症药",
                        "大中华商业权"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}